Conversion from cyclosporin A to tacrolimus is safe and decreases blood pressure, cholesterol levels and TGF-β1 type I receptor expression
- 1 August 2001
- journal article
- research article
- Published by Wiley in Clinical Transplantation
- Vol. 15 (4) , 276-283
- https://doi.org/10.1034/j.1399-0012.2001.150410.x
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Quantitative flow cytometry to measure the TNF-α and IL-2 system after heart transplantationTransplant International, 2000
- Quantitative flow cytometry to measure the TNF- α and IL-2 system after heart transplantationTransplant International, 2000
- TGF-?? EXPRESSION IN RENAL TRANSPLANT BIOPSIESTransplantation, 2000
- Intragraft platelet-derived growth factor-α and transforming growth factor-β1 during the development of accelerated graft vascular disease after clinical heart transplantationTransplant Immunology, 1999
- Treatment outcome and prognostic factors for relapse after high-dose chemotherapy and peripheral blood stem cell rescue for patients with poor risk high grade non-Hodgkin’s lymphomaBone Marrow Transplantation, 1999
- TRANSFORMING GROWTH FACTOR (TGF)-?? MIMICS AND ANTI-TGF-?? ANTIBODY ABROGATES THE IN VIVO EFFECTS OF CYCLOSPORINETransplantation, 1999
- TGF-β 1 DNA Polymorphisms, Protein Levels, and Blood PressureHypertension, 1999
- Differential effects of cyclosporin A and tacrolimus on the production of TGF- β : implications for the development of obliterative bronchiolitis after lung transplantationTransplant International, 1998
- TGF-β receptor signalingBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1997
- Cyclosporine-Associated Chronic NephropathyNew England Journal of Medicine, 1984